Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
26.72
-2.05 (-7.13%)
At close: Mar 5, 2026, 4:00 PM EST
26.72
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:41 PM EST
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 47.33, with a low estimate of 26 and a high estimate of 56. The average target predicts an increase of 77.13% from the current stock price of 26.72.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 19, 2025.
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $45 → $52 | Strong Buy | Maintains | $45 → $52 | +94.61% | Dec 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $52 → $56 | Strong Buy | Maintains | $52 → $56 | +109.58% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $55 | Buy | Maintains | $50 → $55 | +105.84% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $42 → $52 | Strong Buy | Maintains | $42 → $52 | +94.61% | Oct 30, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $50 | Buy | Maintains | $26 → $50 | +87.13% | Sep 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.47
from -3.66
EPS Next Year
-2.27
from -2.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.31 | -1.83 | ||||
| Avg | -2.47 | -2.27 | ||||
| Low | -2.52 | -2.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.